Patents by Inventor Hongfeng Deng

Hongfeng Deng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted azetidinones
    Publication number: 20070105832
    Abstract: Compounds are provided which have the structure Wherein A, B, C, D, m, Y, Ra, Rc, Rd, and Rd? are as described herein, and which are useful as inhibitors of tryptase, thrombin, trypsin, Factor Xa, Factor VIIa, Factor XIa, and urokinase-type plasminogen activator and may be employed in preventing and/or treating asthma, chronic asthma, allergic rhinitis, and thrombotic disorders.
    Type: Application
    Filed: April 4, 2006
    Publication date: May 10, 2007
    Inventors: Thomas Bannister, Cassandra Celatka, Nizal Chandrakumar, Hongfeng Deng, Zihong Guo, Lei Jin, Tsvetelina Lazarova, Jian Lin, Scott Moe, Pamela Nagafuji, Manuel Navia, Amy Ripka, Michael Rynkiewicz, Kerry Spear, James Stickler, Roger Xie
  • Receptor selective cannabimimetic aminoalkylindoles
    Patent number: 7173027
    Abstract: Disclosed are cannabimimetic aminoalkylindole compounds and methos for their manufacture. The disclosed compounds are surprisingly potent and selective cannabinoinds. Also disclosed are methods of using the disclosed compounds, including use of the disclosed compounds to stimulate a cannabinoid receptor, to provide a physiological effect in an animal or individual and to treat a condition in an animal or individual.
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: February 6, 2007
    Assignee: University of Connecticut
    Inventors: Alexandros Makriyannis, Hongfeng Deng
  • Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
    Publication number: 20060223866
    Abstract: The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.
    Type: Application
    Filed: February 6, 2006
    Publication date: October 5, 2006
    Applicant: Praecis Pharmaceuticals, Inc.
    Inventors: Ghotas Evindar, Hongfeng Deng, Barry Morgan
  • (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
    Patent number: 6949574
    Abstract: The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: September 27, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sing-Yuen Sit, Kai Xie, Hongfeng Deng
  • Compounds and methods for treatment of thrombosis
    Publication number: 20050143317
    Abstract: The present invention provides compounds that inhibit Factor XIa and methods of preventing or treating undesired thrombosis by administering a compound of the invention to a mammal. The invention also provides three-dimensional structures of Factor XIa and methods for designing or selecting additional Factor XIa inhibitors using these structures.
    Type: Application
    Filed: April 2, 2004
    Publication date: June 30, 2005
    Inventors: Sherin Abdel-Meguid, Robert Babine, Hongfeng Deng, Lei Jin, Jian Lin, Scott Magee, Harold Meyers, Pramod Pandey, Michael Rynkiewicz, David Weaver, Zihong Gho, Thomas Bannister
  • (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
    Publication number: 20050131032
    Abstract: The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.
    Type: Application
    Filed: January 19, 2005
    Publication date: June 16, 2005
    Inventors: Sing-Yuen Sit, Kai Xie, Hongfeng Deng
  • Cannabimimetic indole derivatives
    Publication number: 20050119234
    Abstract: Cannabimimetic indole derivatives are presented which have preferentially high affinities for one of the cannabinoid CB1 or CB2 receptor sites. The improved receptor affinity makes these analogs therapeutically useful as medications in individuals and animals.
    Type: Application
    Filed: November 5, 2004
    Publication date: June 2, 2005
    Applicant: University of Connecticut
    Inventors: Alexandros Makriyannis, Hongfeng Deng
  • Cannabimimetic indole derivatives
    Patent number: 6900236
    Abstract: Novel cannabimimetic indole derivatives are presented which have preferential high affinities for one of the cannabinoid CB1 CB2 receptor sites. The improved receptor affinity makes these analogs therapeutically useful as medications in individuals and animals for treatment of pain, glaucoma, epilepsy, nausea associated with chemotherapy.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: May 31, 2005
    Assignee: University of Connecticut
    Inventors: Alexandros Makriyannis, Hongfeng Deng
  • Novel cannabimimetic ligands
    Publication number: 20040077649
    Abstract: Disclosed are heterocyclic compounds and methods for their manufacture. The disclosed compounds are surprisingly potent and selective cannabinoids. Also disclosed are methods of using the disclosed compounds, including use of the disclosed compounds to stimulate a cannabinoid receptor, to provide a physiological effect in an animal or individual and to treat a condition in an animal or individual.
    Type: Application
    Filed: October 31, 2003
    Publication date: April 22, 2004
    Inventors: Alexandros Makriyannis, Hongfeng Deng
  • Receptor selective cannabimimetic aminoalkylindoles
    Publication number: 20040077851
    Abstract: Disclosed are cannabimimetic aminoalkylindole compounds and methos for their manufacture. The disclosed compounds are surprisingly potent and selective cannabinoinds. Also disclosed are methods of using the disclosed compounds, including use of the disclosed compounds to stimulate a cannabinoid receptor, to provide a physiological effect in an animal or individual and to treat a condition in an animal or individual.
    Type: Application
    Filed: July 25, 2003
    Publication date: April 22, 2004
    Inventors: Alexandros Makriyannis, Hongfeng Deng
  • (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
    Publication number: 20030195226
    Abstract: The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.
    Type: Application
    Filed: February 4, 2003
    Publication date: October 16, 2003
    Inventors: Sing-Yuen Sit, Kai Xie, Hongfeng Deng